Clinical Trials

130 enrolled

Plasma cell

Multiple Myeloma

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

31 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06241456 2025-12-09

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Recruiting

351 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05950334 2025-08-22

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

20 enrolled

Lymphoma, B-Cell

NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

26 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

50 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

72 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

98 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05934097 2023-07-06

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02954406 2022-02-18

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

43 enrolled 27 charts

Lymphoma, Non-Hodgkin

NCT01594229 2021-08-02

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

60 enrolled

Lymphoma, Non-Hodgkin, Neoplasms

NCT00794638 2021-07-02

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

9 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02162888 2021-06-07

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

81 enrolled

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

87 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT03604679 2021-04-27

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

18 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00389051 2020-10-22

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

9 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT01671904 2020-10-14

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

84 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02006485 2019-11-05

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

160 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01691807 2018-02-28

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

30 enrolled

Lymphoma, Non-Hodgkin, Neoplasms

NCT01317901 2017-06-28

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

12 enrolled 15 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01831505 2017-02-27

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

4 enrolled

Lymphoma

NCT01300247 2017-02-02

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

41 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00825149 2016-11-04

GAUDI

137 enrolled

Lymphoma, Non-Hodgkin

NCT00872976 2013-07-22

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Phase 1 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00868413 2013-06-07

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

32 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00863850 2012-04-23

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy